Hormone therapy affects plasma measures of factor VII-activating protease in younger postmenopausal women

References

• Lowe GD. Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease. J Intern Med 2004;256:361–374
   PubMed Web of Science ®Google Scholar
• Sidelmann JJ, Jespersen J, Andersen LF, Skouby SO. Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study. BJOG 2003;110:541–547
   PubMed Web of Science ®Google Scholar
• Bladbjerg EM, Skouby SO, Andersen LF, Jespersen J. Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. Hum Reprod 2002;17:3235–3241
   PubMed Web of Science ®Google Scholar
• Bladbjerg EM, Madsen JS, Kristensen SR, et al Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. J Thromb Haemost 2003;1:1208–1214
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Lobo R. What is the cardioprotective role of hormone replacement therapy? Curr Atheroscler Rep 2003;5:56–66
   PubMedGoogle Scholar
• van de Weijer PH. Risks of hormone therapy in the 50–59 year age group. Maturitas 2008;60:59–64
   PubMed Web of Science ®Google Scholar
• Shapiro S. Oral contraceptives, hormone therapy and cardiovascular risk. Climacteric 2008;11:355–363
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–1477
   PubMed Web of Science ®Google Scholar
• Rees M, Stevenson J. Primary prevention of coronary heart disease in women. Menopause Int 2008;14:40–45
   PubMedGoogle Scholar
• Lobo RA. Postmenopausal hormones and coronary artery disease: potential benefits and risks. Climacteric 2007;10(Suppl 2):21–26
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ. Postmenopausal hormone therapy and cardiovascular disease in perspective. Clin Obstet Gynecol 2008;51:564–580
   PubMed Web of Science ®Google Scholar
• Barlow DH. The medical management of menopause: to treat or not to treat? Ann NY Acad Sci 2008;1127:134–139
   PubMed Web of Science ®Google Scholar
• Kanse SM, Parahuleva M, Muhl L, Kemkes-Matthes B, Sedding D, Preissner KT. Factor activating protease (FSAP): vascular functions and role in atherosclerosis. Thromb Haemost 2008;99:286–289
   PubMed Web of Science ®Google Scholar
• Romisch J, Feussner A, Vermohlen S, Stohr HA. A protease isolated from human plasma activating factor VII independent of tissue factor. Blood Coagul Fibrinolysis 1999;10:471–479
   PubMed Web of Science ®Google Scholar
• Sidelmann JJ, Vitzthum F, Funding E, Munster AM, Gram J, Jespersen J. Factor VII-activating protease in patients with acute deep venous thrombosis. Thromb Res 2008;122:848–853
   PubMed Web of Science ®Google Scholar
• Kannemeier C, Al Fakhri N, Preissner KT, Kanse SM. Factor VII-activating protease (FSAP) inhibits growth factor-mediated cell proliferation and migration of vascular smooth muscle cells. FASEB J 2004;18:728–730
   PubMed Web of Science ®Google Scholar
• Parahuleva MS, Kanse SM, Parviz B, et al Factor seven activating protease (FSAP) expression in human monocytes and accumulation in unstable coronary atherosclerotic plaques. Atherosclerosis 2008;196:164–171
   PubMed Web of Science ®Google Scholar
• Ireland H, Miller GJ, Webb KE, Cooper JA, Humphries SE. The factor VII activating protease G511E (Marburg) variant and cardiovascular risk. Thromb Haemost 2004;92:986–992
   PubMed Web of Science ®Google Scholar
• Franchi F, Martinelli I, Biguzzi E, Bucciarelli P, Mannucci PM. Marburg I polymorphism of factor VII-activating protease and risk of venous thromboembolism. Blood 2006;107:1731
   PubMed Web of Science ®Google Scholar
• Weisbach V, Ruppel R, Eckstein R. The Marburg I polymorphism of factor VII-activating protease and the risk of venous thromboembolism. Thromb Haemost 2007;97:870–872
   PubMed Web of Science ®Google Scholar
• van Minkelen R, de Visser MC, Vos HL, Bertina RM, Rosendaal FR. The Marburg I polymorphism of factor VII-activating protease is not associated with venous thrombosis. Blood 2005;105:4898
   PubMed Web of Science ®Google Scholar
• Hoppe B, Tolou F, Radtke H, Kiesewetter H, Dorner T, Salama A. Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism. Blood 2005;105:1549–1551
   PubMed Web of Science ®Google Scholar
• Hoppe B, Tolou F, Dorner T, Kiesewetter H, Salama A. Gene polymorphisms implicated in influencing susceptibility to venous and arterial thromboembolism: frequency distribution in a healthy German population. Thromb Haemost 2006;96:465–470
   PubMed Web of Science ®Google Scholar
• Hoppe B, Dorner T, Kiesewetter H, Salama A. Marburg I polymorphism of factor VII-activating protease and risk of recurrent venous thromboembolism. Thromb Haemost 2006;95:907–908
   PubMed Web of Science ®Google Scholar
• Gulesserian T, Hron G, Endler G, Eichinger S, Wagner O, Kyrle PA. Marburg I polymorphism of factor VII-activating protease and risk of recurrent venous thromboembolism. Thromb Haemost 2006;95:65–67
   PubMed Web of Science ®Google Scholar
• Willeit J, Kiechl S, Weimer T, et al Marburg I polymorphism of factor VII-activating protease: a prominent risk predictor of carotid stenosis. Circulation 2003;107:667–670
   PubMed Web of Science ®Google Scholar
• Skouby SO, Gram J, Andersen LF, Sidelmann J, Petersen KR, Jespersen J. Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations. Am J Obstet Gynecol 2002;186:969–977
   PubMed Web of Science ®Google Scholar
• Stephan S, Schwarz H, Borchert A, et al Tests for the measurement of factor VII-activating protease (FSAP) activity and antigen levels in citrated plasma, their correlation to PCR testing, and utility for the detection of the Marburg I-polymorphism of FSAP. Clin Chem Lab Med 2008;46:1109–1116
   PubMed Web of Science ®Google Scholar
• Phillips LS, Langer RD. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertil Steril 2005;83:558–566
   PubMed Web of Science ®Google Scholar
• Manson JE, Allison MA, Rossouw JE, et al Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591–2602
   PubMed Web of Science ®Google Scholar